Shares of PetIQ Inc (NASDAQ:PETQ) have been assigned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $41.14.
Several equities analysts have recently weighed in on PETQ shares. ValuEngine cut PetIQ from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded PetIQ from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Friday, August 9th. Guggenheim started coverage on PetIQ in a research report on Thursday, May 23rd. They issued a “buy” rating and a $35.00 price target for the company. Finally, BidaskClub cut PetIQ from a “buy” rating to a “hold” rating in a research report on Thursday.
Shares of PETQ traded down $1.09 during mid-day trading on Friday, hitting $31.07. The stock had a trading volume of 11,740 shares, compared to its average volume of 491,942. The company has a market capitalization of $906.91 million, a price-to-earnings ratio of 24.98, a P/E/G ratio of 1.26 and a beta of 2.06. The stock’s fifty day moving average price is $34.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.51 and a current ratio of 2.89. PetIQ has a 52 week low of $21.29 and a 52 week high of $43.93.
PetIQ (NASDAQ:PETQ) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.35. The company had revenue of $220.60 million during the quarter, compared to analysts’ expectations of $193.89 million. PetIQ had a return on equity of 10.54% and a net margin of 0.68%. The firm’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.66 earnings per share. As a group, research analysts predict that PetIQ will post 1.07 earnings per share for the current year.
In other news, insider Will Santana sold 20,000 shares of PetIQ stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $28.16, for a total value of $563,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 110,291 shares of company stock valued at $3,436,491. 23.79% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Waddell & Reed Financial Inc. raised its position in PetIQ by 11.4% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 1,780,931 shares of the company’s stock valued at $58,699,000 after purchasing an additional 182,205 shares during the last quarter. Nuveen Asset Management LLC bought a new position in PetIQ during the 2nd quarter valued at approximately $2,356,000. UBS Asset Management Americas Inc. bought a new position in PetIQ during the 2nd quarter valued at approximately $313,000. AQR Capital Management LLC raised its position in PetIQ by 4.0% during the 2nd quarter. AQR Capital Management LLC now owns 9,620 shares of the company’s stock valued at $317,000 after purchasing an additional 367 shares during the last quarter. Finally, Marshall Wace North America L.P. raised its position in PetIQ by 1,205.8% during the 2nd quarter. Marshall Wace North America L.P. now owns 57,428 shares of the company’s stock valued at $1,893,000 after purchasing an additional 53,030 shares during the last quarter. Institutional investors and hedge funds own 89.80% of the company’s stock.
PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.
See Also: Debt-To-Equity Ratio
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.